UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2023
Commission File Number: 001-39950
Evaxion Biotech A/S
(Exact Name of Registrant as Specified in Its Charter)
Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXPLANATORY NOTE
This Amendment to the Report on Form 6-K originally filed with the Securities and Exchange Commission on August 17, 2023 (the “Form 6-K”), is being filed solely for the purposes of furnishing a corrected press release. The corrected press release updates the time of the webcast to 10:00 a.m. EDT from 8:00 a.m. EDT on Tuesday, August 22.
Furnished as Exhibit 99.1 to this Report on Form 6-K is the corrected press release of Evaxion Biotech A/S (the “Company”) dated August 18, 2023, announcing the Company’s financial results for the three months ended June 30, 2023.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | Evaxion Biotech A/S |
| | |
| Date: August 18, 2023 | By: | /s/ Per Norlén |
| | | Per Norlén
Chief Executive Officer |
